

Erratum

S. G. Gray et al. *The Insulin-like Growth Factors and Insulin-signaling Systems: An Appealing Target for Breast Cancer Therapy?* *Horm Metab Res* 2003; 35: 857–871 and *Erratum Horm Metab Res* 2004; 36: 74

Figure 1 was printed in black and white but should have been printed in colours as shown below:




Fig. 1 Receptor Tyrosine Kinases. This figure is adapted from [100], updated with information compiled from multiple references and various databases such as Pfam. We found that all published figures on the domain organisation of RTKs contain inaccuracies and discrepancies, which we have tried to correct and reconcile. We would be grateful if any remaining error or omission was reported to us. The RTKs in bold type have been implicated in human malignancies.

- | | |
|---|------------------------------|
| 1 ErbB1 (EGFR), ErbB2, ErbB3, ErbB4
(ErbB3 is a dead kinase) | 10 Axl, Mer, Eyk, Tyro3, Nyk |
| 2 INSR, IGF-IR, IRRR | 11 Tie, Tek (Tie2) |
| 3 PDGFRα, PDGFRβ, CSF1R (c-Kit), Flk2 | 12 Eph A1–8, B1–6 |
| 4 VEGFR (Flt1), Flt4, KDR | 13 Ret |
| 5 FGFR 1–4 | 14 Ryk |
| 6 TRKA, TRKB, TRKC | 15 DDR1, DDR2 |
| 7 Ror1, Ror2 | 16 Ros |
| 8 MusK | 17 AATYK |
| 9 Met (HGFR/scatter factor receptor), Ron, Sea | 18 ALK, LTK |
| | 19 PTK7, KLG |